首页>
外国专利>
Use of sodium-hydrogen ion antiporter 1 inhibitors e.g. N-(4,5-bis-methanesulfonyl-2-methyl-2-methyl-benzoyl)-guanidine, used at doses causing only partial inhibition, e.g. for treating arrhythmia or angina
Use of sodium-hydrogen ion antiporter 1 inhibitors e.g. N-(4,5-bis-methanesulfonyl-2-methyl-2-methyl-benzoyl)-guanidine, used at doses causing only partial inhibition, e.g. for treating arrhythmia or angina
Use of sodium-hydrogen ion (Na+/H+) antiporter 1 (NHE1) inhibitors (I) is claimed in the production of medicaments for treating or preventing diseases, where NHE1 is only partially inhibited : An independent claim is included for pharmaceutical compositions (A) containing (I), where NHE1 is only partially inhibited by administration of (A). ACTIVITY : Antiarrhythmic; Antianginal; Cardiant; Cerebroprotective; Vasotropic; Antiarteriosclerotic; Antidiabetic; Cytostatic; Antiinflammatory; Hypotensive. In tests in rats with myocardial infarction surgically induced by ligation, N-(4,5-bis-methanesulfonyl-2-methyl-2-methyl-benzoyl)-guanidine (Ia) was administered orally (at 200 ppm in feed), for 3 months starting 2 weeks after ligation, to give a plasma level of 500 ng/ml (causing 75% inhibition of NHE1) initially and 238 ng/ml (causing 60% inhibition of NHE1) after 3 months. Cardiac hypertrophy was completely prevented. MECHANISM OF ACTION : NHE1 inhibitor. In a test, (Ia) exhibited an IC50 value of 455 nM for inhibition of human platelet NHE1.
展开▼
机译:要求保护钠氢离子(Na + / H +>)转运蛋白1(NHE1)抑制剂(I)在生产用于治疗或预防疾病的药物中,其中仅部分抑制NHE1:包括独立权利要求的药物组合物(A)含有(I),其中NHE1仅通过施用(A)被部分抑制。活动:抗心律失常;抗心绞痛卡迪恩脑保护变压性抗动脉硬化;抗糖尿病细胞抑制消炎(药;低血压。在通过结扎手术诱发的心肌梗死大鼠的试验中,口服N-(4,5-双-甲磺酰基-2-甲基-2-甲基-苯甲酰基)-胍(Ia)(饲料中200 ppm),在结扎后2周开始的3个月内,血浆水平最初为500 ng / ml(引起NHE1抑制75%),在3个月后达到238 ng / ml(引起NHE1抑制60%)。完全避免了心脏肥大。作用机理:NHE1抑制剂。在一项测试中,(Ia)对抑制人血小板NHE1的IC50值为455 nM。
展开▼